What is 5-Amino-1MQ?
5-Amino-1MQ is a quinolinium-derived small molecule that inhibits nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and connects NAD+ metabolism with methyl-donor balance. It is grouped in peptide catalogs because it is sold in the same metabolic-optimization market, but chemically it is not a peptide. [2][4]
The biological rationale comes from NNMT work in adipose tissue. NNMT knockdown protected mice from diet-induced obesity, and 5-amino-1MQ reversed several high-fat-diet changes in mice by raising intracellular NAD+ and SAM and shifting adipocyte energy metabolism. [1][2]
The naming can be misleading because 5-Amino-1MQ appears in peptide-oriented catalogs even though it is a small molecule. 5-Amino-1MQ, 5-amino-1-methylquinolinium, and NNMT inhibitor labels should be read as chemistry and target names, not as proof that products are interchangeable. [2][5]
What 5-Amino-1MQ is investigated for
5-Amino-1MQ evidence is grouped by practical use case and oral and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Fat loss without appetite suppression
Oral, Injectable
Fat loss without appetite suppression
Oral, Injectable
NAD+ and cellular energy metabolism
Oral
NAD+ and cellular energy metabolism
Oral
Cholesterol and lipid markers
Oral, Injectable
Cholesterol and lipid markers
Oral, Injectable
Cholesterol claims should be framed as a preclinical metabolic-marker signal, not established lipid management. [2]
Human evidence
No human lipid trial has tested whether 5-Amino-1MQ changes cholesterol, triglycerides, or cardiometabolic risk markers. [2]
Animal / mechanistic evidence
The 11-day diet-induced-obesity mouse experiment reported lower total cholesterol along with lower fat mass after direct 5-amino-1MQ treatment. [2]
Evidence snapshot
Overall confidence
5-Amino-1MQ remains a preclinical metabolic candidate. Mouse NNMT-inhibition studies and a coherent target rationale support interest, but no human outcome, pharmacokinetic, or chronic-safety trial has established practical use. [2][1]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
No published human trial establishes efficacy, dosing, pharmacokinetics, or chronic safety for 5-Amino-1MQ. [6][5]
Animal / preclinical
Mouse NNMT-inhibition studies are the strongest outcome evidence, with adiposity and energy-expenditure endpoints. That still leaves the evidence model-based for human use. [1][2]
Mechanism support
NNMT connects nicotinamide methylation, NAD+ availability, SAM balance, and adipocyte metabolism. The target is coherent, but clinical translation is unproven. [4][5]
Forms & administration
5-Amino-1MQ is most commonly discussed as oral capsules in compounded-market protocols. Injectable context comes from preclinical mouse work rather than an app-ready human route. [2][6]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Common oral range is 50-100 mg once daily. Injectable mouse-study routes should not be translated into oral scheduling. [2][5]
Frequency
Once-daily morning dosing is the simplest app schedule for oral use. Human pharmacokinetic data do not define a split-dose pattern. [5]
Timing Considerations
Morning timing is the usual anchor for metabolic logging and keeps appetite, energy, and glucose notes easier to compare. [4]
Cycle Length
Common cycles run 8-12 weeks. Body weight, waist, glucose, lipids, and tolerability are the usual reassessment points. [5]
What to expect
Weeks 2-4
Oral metabolic use usually feels quiet at first; appetite, energy, GI comfort, weight trend, and waist changes are the recognizable early signals. [5]
Weeks 8-12
Body-composition and metabolic-lab trends become easier to compare with diet, training, and medication changes over a full oral cycle. [1][2]
After stopping
Weight, appetite, and lab markers may drift back toward baseline after the cycle because human durability and washout data are missing. [5]
Safety profile
For oral or other research-market use, practical safety attention belongs on product identity, GI or neurologic tolerability, liver metabolism, and signals that chronic NNMT inhibition could affect broader methylation or cancer-related biology. Human pharmacokinetics and long-term exposure are still not characterized. [5][4]
Who 5-Amino-1MQ is not for
Route-specific avoid and medical-review notes:
-
Pregnancy or breastfeeding
Avoid because human reproductive safety and developmental effects of NNMT modulation are unknown. [5]
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- NAD+ precursors
NMN or NR may amplify NAD-related pathway changes when paired with oral NNMT inhibition; this is a theoretical mechanism-and-dose gap. [4]
- One-carbon or methylation pathway drugs
Methylation-pathway drugs or high-dose methyl donors could make SAM and nicotinamide effects harder to interpret with oral 5-Amino-1MQ; this is a theoretical pathway caution. [2]
Pairing notes
Regulatory status
United States
5-Amino-1MQ has no FDA-approved oral or injectable drug use as of 2026-06-21. Availability as a research chemical or compounded preparation does not create FDA review of safety, effectiveness, quality, or human-use claims. [6][8]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved As of 2026-06-21, 5-Amino-1MQ was not FDA-approved as an oral or injectable drug. Research-market or compounded availability does not equal FDA approval. [6][8] | Not Listed As of 2026-06-21, 5-Amino-1MQ was not identified on FDA's reviewed 503A bulk-substance materials for oral or injectable compounding. Compounded preparations are still not FDA-approved drugs. [7][8] |
| Injectable | Not Approved As of 2026-06-21, 5-Amino-1MQ was not FDA-approved as an oral or injectable drug. Research-market or compounded availability does not equal FDA approval. [6][8] | Not Listed As of 2026-06-21, 5-Amino-1MQ was not identified on FDA's reviewed 503A bulk-substance materials for oral or injectable compounding. Compounded preparations are still not FDA-approved drugs. [7][8] |
Oral
Injectable
International
EU/Europe, UK, Canada, and Australia should be checked by local product and claim; no approved therapeutic 5-Amino-1MQ product was found in the reviewed official sources.
Sports & competition
WADA's 2026 Prohibited List does not specifically name 5-Amino-1MQ, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review. [9]
How it works
5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide hormone. NNMT converts nicotinamide into 1-methylnicotinamide and uses methyl-donor capacity; in fat-cell and mouse obesity models, lowering NNMT shifts adipose metabolism toward greater energy expenditure rather than appetite suppression. [2][1][4]
The practical mechanism is still target-based, not outcome-proven in humans. Oral or injectable exposure has to reach the right tissues, inhibit NNMT selectively, and avoid chronic methylation or cancer-biology problems before mouse fat-loss biology can reliably support an adult human outcome claim. [2][4][5]
Research gaps & open questions
What the current literature has not yet settled about 5-Amino-1MQ:
Human pharmacokinetic, oral-bioavailability, and dose-ranging studies would be needed before practical dosing confidence can rise. [5]
Long-term NNMT inhibition needs oncology, hepatic, metabolic, and methylation-pathway safety data. [4][5]
Human body-composition trials should measure weight, fat mass, waist, appetite, glucose, lipids, and discontinuation durability. [2]
Common questions
Is 5-Amino-1MQ actually a peptide?
No. It is a small-molecule NNMT inhibitor that is discussed alongside metabolic peptides because of how it is marketed and used in optimization settings. [2]
Does 5-Amino-1MQ work for human fat loss?
Myths & misconceptions
History & discovery
5-Amino-1MQ entered peptide-adjacent discussions through NNMT obesity biology rather than peptide discovery: researchers first linked adipose NNMT to energy metabolism, then used a small-molecule inhibitor to probe that target. [1][2]
Mouse knockdown work showed that reducing NNMT in white adipose tissue protected against diet-induced obesity, making the enzyme a plausible metabolic target. [1]
A medicinal-chemistry paper described 5-amino-1MQ as a selective, membrane-permeable NNMT inhibitor and reported anti-obesity effects in high-fat-diet mice. [2]
Recent NNMT reviews shifted the discussion toward drug-development feasibility, while noting that human efficacy, dosing, and safety questions remain unresolved for inhibitors. [4][5]
9 studies
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.
Nature, 2014 Apr 10. review.
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.
Biochemical pharmacology, 2018 Jan. animal.
Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.
Scientific reports, 2022 Jan 10. animal.
Exploring NNMT: from metabolic pathways to therapeutic targets.
Archives of pharmacal research, 2024 Dec. review.
Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation.
Trends in pharmacological sciences, 2026 Jun. review.
Drugs@FDA/openFDA query for 5-Amino-1MQ
U.S. Food and Drug Administration / openFDA. database query.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
U.S. Food and Drug Administration, 2026-05-14. regulatory.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency, 2026. regulatory.